Clone 6f11

Manufactured by Roche

The Clone 6F11 is a laboratory equipment product developed by Roche. It is a tool used for cell line authentication and identification. The core function of the Clone 6F11 is to facilitate the detection and verification of cell lines through specific cellular markers.

Automatically generated - may contain errors

Lab products found in correlation

Clone 1e2, by Roche (3 mentions) Clone 4b5, by Roche (1 mentions) Benchmark autostainer, by Roche (1 mentions)

Close spelling variants of this product

CONFIRM™ mouse anti-ER antibody (clone 6F11) (3 citations)

3 protocols using clone 6f11

Biomarker Concordance in Primary and Metastatic Breast Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fixation times ranged from six to 48 hours. Immunohistochemical (IHC)
stains for ER, PR and HER2 were performed in 5 μm-thick whole tissue
sections, or in cell blocks (CBs) fixed in CytoLyt® or formalin. FDA
approved monoclonal antibodies for ER (Ventana; clone 6F11), PR (Ventana; clone
1E2), and HER2 (Ventana; clone 4B5) were utilized for IHC testing, with positive
and negative controls. The hematoxylin and eosin (H&E) and IHC slides
were re-reviewed by 2 pathologists (ME and RDJ); interpretation of ER, PR and
HER2 IHC, and HER2 fluorescence in situ hybridization (FISH) results were done
following the ASCO/CAP guidelines.^{14 (link),15 (link)} ER and PR
discordance between the PBC and the MBC was defined as a switch in the receptor
status from positive to negative, or from negative to positive. HER2 status was
determined following the integrated evaluation of IHC and FISH results. HER2
discordance between the PBC and MBC was defined as a switch from HER2 positive
to negative, or HER2 negative to positive. Cases with HER2 status changes
between the PBC and MBC from positive or negative to equivocal, or vice-versa,
were considered concordant.

Pareja F., Murray M.P., Jean R.D., Konno F., Friedlander M., Lin O, & Edelweiss M. (2017). Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma. Journal of the American Society of Cytopathology, 6(1), 33-40.

+ Open protocol

+ Expand

Breast Cancer Molecular Subtyping Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Her2/neu testing was carried out at a single pathology laboratory in Modena by immunohistochemistry, and the results were scored as follows: 0, 1 = negative, 2 = indeterminate, and 3 = positive. Patients with HER2 test results reported as “indeterminate” were evaluated by fluorescence in situ hybridization (FISH). ER and PgR testing were conducted with a single report format of “positive” or “negative” test results, as measured by immunohistochemical analysis (clone 6F11, Ventana, for ER; and clone 1E2, Ventana, for PgR) and staining by Ventana Benchmark autostainer. ER and PgR receptor status were tested by evaluating the percentage of nuclear immunoreactivity with respect to all the nuclei in the neoplastic cells, independently of the staining intensity. Nuclear staining 10% of either ER or PgR was considered a positive result. Ki-67 labeling index was determined with the MIB1 monoclonal antibody as nuclear immunoreactivity. The cut-off was equal to 14% to subdivide luminal A and luminal B tumor. Luminal A were tumors with ER/PgR/HER2-/Ki67 < 14%, luminal B were tumors with ER/PgR/HER2-/Ki67 ≥ 14%, luminal/HER2 enriched were tumors with ER/PgR/HER2, triple-negative tumors were ER-/PgR-/HER2-, and HER2 were tumors with ER-/PgR-/HER2.

Cortesi L., Sebastiani F., Iannone A., Marcheselli L., Venturelli M., Piombino C., Toss A, & Federico M. (2020). Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study. Cancers, 12(7), 1709.

+ Open protocol

+ Expand

Estrogen and Progesterone Receptor Evaluation

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Clone 6 F11 and clone 1E2 (Ventana Medical Systems, Inc., Tucson, AZ) were used for estrogen and progesterone receptor evaluation, respectively. With the Allred score, the proportion score and the intensity score are assessed in six and four grades, respectively 0-5 and 0-3, then the total score is assessed in eight grades (0 and 2-8) [16 (link)]. Tumors with an immunohistochemistry (IHC) total score of 3 were reported as positive. A score index of 0, 1, 2, and 3 was used, corresponding to negative, weak, moderate, and strong staining intensity, respectively, and the percentage of positive cells at each intensity was estimated subjectively. HER2/neu scores of 0-1 were considered negative, whereas a score of 3 was reported as positive (DAKO). Chromogenic in-situ hybridization or fluorescence in-situ hybridization analyses were performed in cases with IHC total score of 2.

Miolo G., Muraro E., Martorelli D., Lombardi D., Scalone S., Spazzapan S., Massarut S., Perin T., Viel E., Comaro E., Talamini R., Bidoli E., Turchet E., Crivellari D, & Dolcetti R. (2014). Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 14, 954.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!